<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427646</url>
  </required_header>
  <id_info>
    <org_study_id>18445</org_study_id>
    <nct_id>NCT02427646</nct_id>
  </id_info>
  <brief_title>Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease</brief_title>
  <official_title>Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western University, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study attempts to fill a critical knowledge gap of BoNT A in tremor management by
      studying the efficacy of IncobotulinumtoxinA (Xeomin®) injection for hand tremor in essential
      tremor and idiopathic Parkinson disease using data regarding composition of tremor obtained
      through sophisticated, yet clinically accessible multi-sensor based kinematic information.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Tremor Severity</measure>
    <time_frame>96 weeks</time_frame>
    <description>Improvement in hand tremor as determined by an increase &gt;8 points on a standardized clinical assessment tool (Fahn, Tolosa, Marin Tremor Assessment Scale) pre and post Xeomin® injection using kinematic guided injection parameters for both IPD and ET</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinematic Tremor Severity</measure>
    <time_frame>96 weeks</time_frame>
    <description>For two subgroups of participants: (A) those with a &gt; 8 point improvement on the tremor rating scale and (B) those with a change ≤ 8 points on the tremor rating scale, Group A will have 50% reduction in overall tremor amplitude as measured by kinematics.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Tremor</condition>
  <arm_group>
    <arm_group_label>Essential tremor treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson disease tremor treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IncobotulinumtoxinA</intervention_name>
    <description>A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections to treat tremor in the most bothersome upper extremity every 16 weeks over 96 weeks. The study will be extended for those participants who benefited and will receive treatment every 12 weeks over 96 weeks. BoNT-A dose will range from 50-300 U per arm.</description>
    <arm_group_label>Essential tremor treatment</arm_group_label>
    <arm_group_label>Parkinson disease tremor treatment</arm_group_label>
    <other_name>Botulinum neurotoxin type A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consenting male and female participants, aged 18 years to 80 years

          -  PD individuals diagnosed by UK Brain Bank Criteria with stage H&amp;Y2-3 disease or ET
             with hand tremor in their motor dominant hand

          -  Stable IPD/ET medication management for the 6 month duration prior to their enrollment
             in the study

          -  Individuals with IPD will be eligible for the study only if tremor is their primary
             and most bothersome symptom as determined by clinical exam and patient report

          -  Participants who are botulinum toxin naïve for tremor management

        Exclusion Criteria:

          -  History of stroke

          -  Muscle weakness or any related compartmental muscle syndrome

          -  Smoking

          -  Offending medications (Lithium, valproate, steroids, amiodarone, beta-adrenergic
             agonists (e.g. salbutamol))

          -  Contradictions per the Xeomin® drug monograph

          -  Patients prescribed zonisamide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mandar Jog, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Neurological Sciences</affiliation>
  </overall_official>
  <reference>
    <citation>Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992 Mar;56(1):80-99. Review.</citation>
    <PMID>1579114</PMID>
  </reference>
  <reference>
    <citation>Evidente VG, Adler CH. An update on the neurologic applications of botulinum toxins. Curr Neurol Neurosci Rep. 2010 Sep;10(5):338-44. doi: 10.1007/s11910-010-0129-z. Review.</citation>
    <PMID>20567945</PMID>
  </reference>
  <reference>
    <citation>Benito-León J, Louis ED. Essential tremor: emerging views of a common disorder. Nat Clin Pract Neurol. 2006 Dec;2(12):666-78; quiz 2p following 691. Review.</citation>
    <PMID>17117170</PMID>
  </reference>
  <reference>
    <citation>Pullman SL, Elibol B, Fahn S. Modulation of parkinsonian tremor by radial nerve palsy. Neurology. 1994 Oct;44(10):1861-4.</citation>
    <PMID>7936237</PMID>
  </reference>
  <reference>
    <citation>Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996 May;11(3):250-6.</citation>
    <PMID>8723140</PMID>
  </reference>
  <reference>
    <citation>Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12;56(11):1523-8.</citation>
    <PMID>11402109</PMID>
  </reference>
  <reference>
    <citation>Wissel J, Masuhr F, Schelosky L, Ebersbach G, Poewe W. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord. 1997 Sep;12(5):722-6.</citation>
    <PMID>9380055</PMID>
  </reference>
  <reference>
    <citation>Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord. 1994 Nov;9(6):601-9.</citation>
    <PMID>7845399</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>February 17, 2018</last_update_submitted>
  <last_update_submitted_qc>February 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western University, Canada</investigator_affiliation>
    <investigator_full_name>Mandar Jog</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Kinematics</keyword>
  <keyword>Botulinum toxin type A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

